Insights into NEK2 inhibitors as antitumor agents: From mechanisms to potential therapeutics

Yizhen Jiang, Yutong Wang, Feijing Su, Yaqin Hou, Wen Liao, Baichuan Li and Wuyu Mao

European Journal of Medicinal Chemistry, 2025, 286, 117287
DOI: 10.1016/j.ejmech.2025.117287

Involvement of NEK2 and NEK9 in LPS - induced endothelial barrier dysfunction

Nektarios Barabutis and Mohammad S. Akhter

Microvascular Research, 2024, 152, 104651
DOI: 10.1016/j.mvr.2023.104651

Pharmacophore Modeling of Janus Kinase Inhibitors: Tools for Drug Discovery and Exposition Prediction

Florian Fischer, Veronika Temml and Daniela Schuster

Molecules, 2025, 30, 2183
DOI: 10.3390/molecules30102183

Insights into an NEk2 inhibitory profile of nitidine chloride by molecular docking and biological evaluation

Danni Li, Jiahao Lu, Qiying Zhang, Yuzhu Zhou, Long Li, Hua Zhu and Tong Li

BMC Chemistry, 2022, 16
DOI: 10.1186/s13065-022-00870-6

Vinylpyridine as a Tunable Covalent Warhead Targeting C797 in EGFR

Nils Pemberton, Nina Compagne, Argyrides Argyrou, Emma Evertsson, Anders Gunnarsson, Jason G. Kettle, Jonathan P. Orme and Richard A. Ward

ACS Med. Chem. Lett., 2024, 15, 583
DOI: 10.1021/acsmedchemlett.3c00425

One shoot, three birds: Targeting NEK2 orchestrates chemoradiotherapy, targeted therapy, and immunotherapy in cancer treatment

Xing Huang, Gang Zhang, Tianyu Tang, Xiang Gao and Tingbo Liang

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022, 1877, 188696
DOI: 10.1016/j.bbcan.2022.188696

An insight into the rational design of recent purine-based scaffolds in targeting various cancer pathways

Abhishek Chaurasiya, Simranpreet K Wahan, Chandrakant Sahu and Pooja A Chawla

Journal of Molecular Structure, 2023, 1274, 134308
DOI: 10.1016/j.molstruc.2022.134308

Identification of a novel spirocyclic Nek2 inhibitor using high throughput virtual screening

Ashif I. Bhuiyan, Athena H. Choi, Sarbani Ghoshal, Ugochi A. Adiele, Dibyendu Dana, Jun Yong Choi, Karl R. Fath, Tanaji T. Talele and Sanjai K. Pathak

Bioorganic & Medicinal Chemistry Letters, 2023, 88, 129288
DOI: 10.1016/j.bmcl.2023.129288

Exploring the anticancer potential of pyrimidine derivatives via molecular docking and dynamics

Govindasamy Rathika, Settu Mythili, Xavier Prisil Naveentha, Nagarajan Gayathri, Soundararajan Deepa, Raju Prabakaran, Surajit De Mandal, Enketeswara Subudhi and Kalibulla Syed Ibrahim

Discov Appl Sci, 2025, 7
DOI: 10.1007/s42452-025-07840-2

Yashfeen Munib Siddiqui, Ilma Shakeel, Gulam Mustafa Hasan and Md. Imtaiyaz Hassan

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026, 1881, 189523
DOI: 10.1016/j.bbcan.2025.189523

Nek2 Kinase Signaling in Malaria, Bone, Immune and Kidney Disorders to Metastatic Cancers and Drug Resistance: Progress on Nek2 Inhibitor Development

Dibyendu Dana, Tuhin Das, Athena Choi, Ashif I. Bhuiyan, Tirtha K. Das, Tanaji T. Talele and Sanjai K. Pathak

Molecules, 2022, 27, 347
DOI: 10.3390/molecules27020347

Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update

Laura Hillebrand, Xiaojun Julia Liang, Ricardo A. M. Serafim and Matthias Gehringer

J. Med. Chem., 2024, 67, 7668
DOI: 10.1021/acs.jmedchem.3c01825

Imidazole‒sulfonamide hybrid conjugate: A privilege scaffold with significant therapeutic potential

Riham M. Bokhtia

European Journal of Medicinal Chemistry Reports, 2026, 16, 100321
DOI: 10.1016/j.ejmcr.2025.100321

Role of NEK2 in tumorigenesis and tumor progression

Jiliang Xia, Hongyan Zhao, Jacob L. Edmondson, Brian Koss and Fenghuang Zhan

Trends in Molecular Medicine, 2025, 31, 79
DOI: 10.1016/j.molmed.2024.07.013

Imidazoles as Potential Anticancer Agents: An Update on Recent Studies

Pankaj Sharma, Chris LaRosa, Janet Antwi, Rajgopal Govindarajan and Karl A. Werbovetz

Molecules, 2021, 26, 4213
DOI: 10.3390/molecules26144213

Systematic Exploration of Privileged Warheads for Covalent Kinase Drug Discovery

Zheng Zhao and Philip E. Bourne

Pharmaceuticals, 2022, 15, 1322
DOI: 10.3390/ph15111322